Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TTR | P02766 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793591 | 0.85 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL793000 | 0.80 | DPP4 (0.43) | ALDH1A1TTR | |
| SCHEMBL333570 | 0.79 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL8425070 | 0.77 | TTR (0.43) | ALDH1A1TTR | |
| SCHEMBL104060 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TTR | |
| SCHEMBL31619409 | 0.77 | ALDH1A1 (0.54) | ALDH1A1TTR | |
| SCHEMBL7270831 | 0.75 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL4514781 | 0.75 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL14511091 | 0.75 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL5783909 | 0.75 | ALDH1A1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459187-B | Janus Kinase Inhibiting Compounds and Methods | HOFFMANN LA ROCHE | 2015-06-17 | — | — | CN | disclosed |
| US-9056863-B2 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. LUNDBECK A/S (DK) | 2015-06-16 | — | — | US | disclosed |
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2763989-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. Lundbeck A/S (DK) | 2014-08-13 | — | — | EP | disclosed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103209695-A | Azabenzothiazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2013-07-17 | — | — | CN | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| WO-2013034761-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| CN-102459187-A | Janus Kinase Inhibiting Compounds and Methods | HOFFMANN LA ROCHE | 2012-05-16 | — | — | CN | disclosed |
| EP-2440529-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | ATP6V1B2, NDUFS5, MT-ND5 | ALDH1A1 328/4885TTR 3270/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | ALDH1A1 1560/4885TTR 3371/4885 |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | ALDH1A1 1372/4885TTR 134/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | ALDH1A1 1372/4885TTR 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.